Similar Efficacy and Safety of CT-P10 and Reference Rituximab in Patients with Advanced Stage Follicular Lymphoma: Updated Phase III Study Results
Won-Seog Kim(Samsung Medical Center), SuYoung Kim(Celltrion (South Korea)), Christian Buske(University Hospital Ulm), Bertrand Coiffier(Unknown), Larry W. Kwak(The University of Texas MD Anderson Cancer Center), Michinori Ogura(Japanese Red Cross Nagoya Daini Hospital), SangJoon Lee(Celltrion (South Korea))
Cited by 4
Related Papers
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review
|Journal of Clinical Oncology|2008|794
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|604
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|568